Internal Medicine and Dermatology Unit, Reunion University Hospital, Saint Denis, Reunion Island, France.
Statistics and methodological Unit, INSERM CIC 1410, Reunion University Hospital, Saint Denis, Reunion Island, France.
Eur J Intern Med. 2019 Nov;69:25-31. doi: 10.1016/j.ejim.2019.08.010. Epub 2019 Aug 21.
Patients under biological therapy for auto-immune disease are considered immunosuppressed and several recent recommendations highlight the need for vaccination against influenza and pneumococcal infections. The aims of this study were to evaluate influenza and pneumococcal vaccine coverage among patients receiving biological therapy and identify factors associated with vaccine uptake within this population.
A retrospective cross-sectional study was performed in adult patients attending hospitals for an auto-immune/inflammatory disease and treated with biological therapy. Vaccine uptake was evidenced from patient's medical records or from their pharmacist's records. Questionnaires about attitudes and knowledge regarding vaccinations were administered to patients and their physicians. Multivariable logistic regression was used to determine factors significantly associated with influenza and pneumococcal vaccine receipt.
A total of 208 patients were included: 52% female and mean age 50.6 (± 14.7) years. Among them 173 completed the questionnaire while 72 physicians replied. Underlying inflammatory diseases were rheumatisms (46%), bowel diseases (31%) and skin diseases (23%). Vaccine uptake was 28% for influenza, 48% for pneumococcus and 22% received both vaccines. Main factors associated to positive uptake were receiving a prescription from a physician, as well as having a good knowledge of vaccines. Factors limiting vaccination were a negative attitude toward vaccines in general, and belonging to the group of inflammatory bowel diseases.
Vaccine coverage for influenza and pneumococcal infections are low in the patients under biologics for auto-immune/inflammatory disease. Health policies should reinforce information and promotion of these vaccines among these patients but also the prescribers.
接受自身免疫性疾病生物治疗的患者被认为存在免疫抑制,最近的几项建议强调了接种流感疫苗和肺炎球菌疫苗的必要性。本研究旨在评估接受生物治疗的患者的流感疫苗和肺炎球菌疫苗接种率,并确定该人群中疫苗接种率的相关因素。
对在医院就诊的接受生物治疗的自身免疫/炎症性疾病成年患者进行回顾性横断面研究。通过患者的病历或药剂师的记录来证明疫苗接种情况。向患者及其医生发放关于疫苗接种态度和知识的问卷。采用多变量逻辑回归分析确定与流感和肺炎球菌疫苗接种率相关的显著因素。
共纳入 208 例患者:女性占 52%,平均年龄 50.6(±14.7)岁。其中 173 例完成了问卷调查,72 例医生回答了问题。基础炎症性疾病为风湿病(46%)、肠道疾病(31%)和皮肤病(23%)。流感疫苗接种率为 28%,肺炎球菌疫苗接种率为 48%,两种疫苗均接种的比例为 22%。与积极接种相关的主要因素包括从医生处获得处方,以及对疫苗有较好的了解。限制接种的因素主要包括对疫苗的总体负面态度,以及属于炎症性肠病患者。
接受生物治疗的自身免疫/炎症性疾病患者流感和肺炎球菌感染疫苗接种率较低。卫生政策应加强这些患者及其处方医生对这些疫苗的信息和推广。